source · text/markdown
source_481fc23600484834
sha256 cc1cdf17f55878203872dc5b38c50ecc6cafc0cd64ff9b897eb0bc2cf99b3a5d
by researka:v2 · 2026-06-27 14:49:13.780497+04:00
# Adjacent Evidence Brief: Telomere Cancer Effects — full paper ## Abstract Evidence-honesty note: The retained evidence has no direct interventional hard-endpoint evidence; indirect, review-level, adjacent, or mechanistic sources are used only to bound interpretation. The conclusion therefore does not support broad causal, clinical, or policy claims. This synthesis tests the thesis that evidence for Telomere Cancer Effects is context-dependent, separating outcome-specific signals from broader claims and identifying the evidence gaps that should bound interpretation. Telomere biology has been proposed as a unifying lens for cancer risk, prognosis, and treatment-related aging, yet whether measured telomere length (TL) behaves as a net risk marker, a protective factor, or merely a contextual biomarker remains contested across tumor types and analytical designs. Resolving this matters clinically because TL-informed claims are entering preventive counseling, survivorship care, and commercial anti-aging interventions without a clear evidence audit. We conducted an AI-assisted structured evidence synthesis with a fully traceable audit trail, drawing only on source-curated primary studies and systematic reviews, and applying qualitative direction-of-effect coding across mortality, immune, contextual, and frailty outcome classes. The cross-source tensions — short-TL harms in breast and head-and-neck cancer (Sasmita 2025; Andreikos 2024) versus long-TL harms in prostate, skin, and pan-cancer MR analyses (Wan 2023; Chen 2023; Song 2022) — remain unresolved because tumor biology, TL measurement matrix, and confounding by immortalization differ across cohorts, and no bundle source adjudicates between them. Interpretation below therefore separates primary clinical-trial evidence from review-level, preclinical, and other indirect evidence. ## Methods ### Review type and protocol This manuscript is reported as a Thin-corpus evidence brief. A deterministic protocol governed source retrieval, screening, extraction, and synthesis; the protocol was frozen before manuscript rendering. The full audit trail is in the supplementary `methods_pack.json` and the timestamped submission directory `synthesis-telomere_cancer_effects-v06-DAILY-2026-06-27T10-44-06Z`. ### Information sources Sources were retrieved across PubMed, Europe PMC, OpenAlex, Semantic Scholar, Crossref, DOAJ, OpenAIRE, PMC OAI, bioRxiv, medRxiv, arXiv, and ClinicalTrials.gov. Retrieval window: 2026-06-27. ### Search strategy The following topic-anchored queries were executed against the information sources listed above: - `telomere cancer effects aging` - `telomere cancer effects older adults` - `telomere cancer effects randomized controlled trial` - `telomere aging` - `telomere older adults` - `telomere randomized controlled trial` - `cancer aging` - `cancer older adults` - `cancer randomized controlled trial` ### Eligibility criteria - Sources whose primary content addresses telomere cancer effects. - Sources with extractable quantitative or qualitative findings. - Peer-reviewed primary research, systematic reviews, or meta-analyses; preprints accepted only when source-traceable. - Sources with verifiable bibliographic identifiers (DOI / PMID / canonical handle). ### Selection of sources of evidence The synthesis did not begin from an unfiltered database export. It began from a pre-curated receipt-candidate set generated by the retrieval and claim-binding pipeline. Of 194 records in the receipt-candidate union, 74 were classified as source candidates and 26 were admitted as traceable synthesis sources. Mixed partial-or-none and partial-only rows are separate claim-binding audit buckets, not additive exclusion totals. No additional records were excluded after final source admission. ### source admission funnel | Admission bucket | n | |---|---:| | Receipt candidate union | 194 | | Classified source candidates | 74 | | No extractable claims | 41 | | None-only claim binding | 8 | | Mixed partial-or-none claim-binding candidates | 49 | | Partial-only claim-binding candidates | 19 | | Strict high-confidence sources | 3 | | Admitted final sources | 26 | ### Exclusion reasons - No records were excluded at the gates instrumented for this run: the eligibility criteria above were applied during retrieval and claim-binding but produced no post-screening exclusions with recorded counts for this corpus. ### Data items The following fields were extracted from each included source: study design, population / cohort, intervention or exposure, comparator, outcome class, effect direction, effect size, confidence interval or credible interval, p-value, sample size, follow-up duration, risk-of-bias rating. Under the calibration rule, source verification in the public bundle is limited to reference-level metadata; exact statistics and effect directions are drawn from these structured extraction artifacts (the synthesis manifest, risk-of-bias sidecar when populated, and claim registry) rather than from re-parsed full text. ### Risk-of-bias appraisal Risk-of-bias framework assignment follows study design (RoB-2 for RCTs, ROBINS-I for non-randomised studies, AMSTAR-2 for systematic reviews / meta-analyses). Public appraisal claims are limited to populated `risk_of_bias.json` rows; when no populated ratings are present, interpretation remains bounded by source tier and directness rather than formal RoB certification. ### Synthesis approach Evidence-tension synthesis: claims grouped by outcome class (contextual adjacent evidence, dosing and pharmacokinetics, frailty, immune and inflammation, longevity, mechanism, mortality and survival); within-class agreement, disagreement, and directness gaps surfaced explicitly. Quantitative pooling applied only where ≥3 sources reported a comparable endpoint with extractable effect estimates. ### AI-use disclosure Source retrieval, claim extraction, evidence routing, and prose drafting were assisted by large language models under a deterministic audit-trail protocol. Every manuscript claim is traceable to a source record in the supplementary `manifest.json`. Final eligibility and interpretation decisions are author-verified. ### Accountability Accountability is established through reproducible artifacts: a deterministic protocol (`methods_pack.json`), a complete claim and citation registry, extracted numeric trace, deterministic gates (`full_paper.journal_surface.json`, `pre_submit_gate.json`, `artifact_consistency.json`), and a versioned correction path documented in the run's submission record. Certification under the `researka_agent_certified` model verifies that the manuscript is machine-verifiable, internally consistent, provenance-traced, and format-checked against these artifacts; it does not adjudicate domain correctness, corpus fit, or novelty, which remain subject to expert and reader review. ## Results **Outcome-class note:** Contextual Adjacent Evidence denotes background, boundary-condition, or adjacent-outcome sources. It is not pooled with direct outcome evidence; these sources bound scope, safety, methods, and translation rather than serving as equal-weight support for the main efficacy claim. | Evidence domain | Corpus slice | Strongest signal | Directness | Main limitation | |---|---|---|---|---| | Telomere Cancer Effects / Contextual Adjacent Evidence | n=18; claims=480 | significant source statistic in 15/18 sources; receipt-level direction coded unclear | 15 indirect; 3 review | limited corpus depth in this outcome class | | Telomere Cancer Effects / Mortality and Survival | n=3; claims=165 | significant source statistic in 3/3 sources; receipt-level direction coded unclear | 2 indirect; 1 review | limited corpus depth in this outcome class | | Telomere Cancer Effects / Dosing and Pharmacokinetics | n=1; claims=74 | negative signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | | Telomere Cancer Effects / Frailty | n=1; claims=30 | positive signal in 1/1 sources | 1 indirect | single-source slice; hypothesis-generating | | Telomere Cancer Effects / Immune and Inflammation | n=1; claims=61 | no extracted directional signal in 1/1 sources | 1 review | single-source slice; hypothesis-generating | | Telomere Cancer Effects / Longevity | n=1; claims=20 | reported statistic in 1/1 sources; receipt-level direction coded unclear | 1 indirect | single-source slice; hypothesis-generating | | Telomere Cancer Effects / Mechanism | n=1; claims=3 | no extracted directional signal in 1/1 sources | 1 mechanistic | single-source slice; hypothesis-generating | This evidence brief reports outcome packets as a map of retained evidence rather than as a full journal Results narrative or pooled effect estimate. ### Contextual Adjacent Evidence Outcomes Contextual Adjacent Evidence remains a separate Results slice for Telomere Cancer Effects (n=18; claims=480; significant source statistic in 15/18 sources; receipt-level direction coded unclear; 15 indirect; 3 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Alhareeri 2020 (Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive; representative statistic p = 0.004; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Jaeger 2024 (A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized; representative statistic p = 0.01; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Li 2026 (Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk; representative statistic p < 0.05; source-level statistic reported; direction=positive; directness=indirect; tier=B2). - Davidson-Swinton 2026 (Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome ∗; representative statistic P < .0001; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). Direction reconciliation: receipt-level null or unclear coding is conservative claim-level coding. Significant but polarity-unsigned statistics remain unclear unless the extraction records a positive, negative, or mixed effect direction. ### Mortality and Survival Outcomes Mortality and Survival remains a separate Results slice for Telomere Cancer Effects (n=3; claims=165; significant source statistic in 3/3 sources; receipt-level direction coded unclear; 2 indirect; 1 review; limited corpus depth in this outcome class) and is not pooled into adjacent endpoint classes. Source-level findings are: - Sasmita 2025 (Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and; representative statistic P = 0.039; source-level statistic reported; direction=unclear; directness=review; tier=B2). - Ha 2023 (Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective; representative statistic P = .903; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). - Sarkar 2026 (Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer; representative statistic p = 0.0005; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). ### Frailty Outcomes Frailty remains a separate Results slice for Telomere Cancer Effects (n=1; claims=30; positive signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Brouwers 2016 (The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters; representative statistic p=0.88; source-level statistic reported; direction=positive; directness=indirect; tier=B2). ### Immune and Inflammation Outcomes Immune and Inflammation remains a separate Results slice for Telomere Cancer Effects (n=1; claims=61; no extracted directional signal in 1/1 sources; 1 review; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Markozannes 2022 (Systematic review of Mendelian randomization studies on risk of cancer; 61 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=review; tier=B2). ### Longevity Outcomes Longevity remains a separate Results slice for Telomere Cancer Effects (n=1; claims=20; reported statistic in 1/1 sources; receipt-level direction coded unclear; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Liang 2024 (DNA methylation‐based telomere length is associated with HIV infection, physical frailty, cancer, and all‐cause; representative statistic p = 0.3; source-level statistic reported; direction=unclear; directness=indirect; tier=B2). ### Dosing and Pharmacokinetics Outcomes Dosing and Pharmacokinetics remains a separate Results slice for Telomere Cancer Effects (n=1; claims=74; negative signal in 1/1 sources; 1 indirect; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Liu 2026 (The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality; representative statistic p < 0.05; source-level statistic reported; direction=negative; directness=indirect; tier=B2). ### Mechanism Outcomes Mechanism remains a separate Results slice for Telomere Cancer Effects (n=1; claims=3; no extracted directional signal in 1/1 sources; 1 mechanistic; single-source slice; hypothesis-generating) and is not pooled into adjacent endpoint classes. Source-level findings are: - Afolabi 2026 (Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and; 3 extracted claim(s); receipt-level direction is the coded finding; direction=null; directness=mechanistic; tier=C1). ## Limitations The principal limitation is evidence-role imbalance. The retained corpus contains no sources classified primarily as direct clinical evidence, 25 adjacent clinical sources, and 1 mechanistic or model-system source, which means causal interpretation depends on how much weight is assigned to each evidence tier. A second limitation is endpoint heterogeneity. Study-level signals span the contextual adjacent evidence and frailty outcome classes, the contextual adjacent evidence, immune and inflammation, mechanism outcome classes, the dosing and pharmacokinetics outcome class, and no dominant outcome class; these domains cannot be pooled narratively without losing clinically relevant differences in measurement, population, and study design. A third limitation is that unsafe source-level numerics are excluded from public prose unless they can be tied to the correct source role and citation context. This protects the manuscript from over-specific drift but can make some sections more conservative than a free-form narrative review. ## Conclusion For telomere cancer effects, the final interpretation is deliberately tiered: the retained clinical and adjacent evidence profile defines a bounded geroscience rationale, but the corpus does not support treating mechanistic target engagement, intermediate biomarkers, and patient-relevant outcomes as interchangeable evidence. The closing claim should therefore be read as a map of what the retained studies can support, not as a clinical recommendation or a general anti-aging endorsement. Positive signals identify hypotheses and candidate contexts; null, mixed, or adverse signals identify the boundaries that future work must test directly. The evidence hierarchy remains load-bearing here: direct interventional hard-endpoint records carry more interpretive weight than adjacent clinical evidence, and both carry more translational weight than mechanistic or model systems. A stronger future conclusion would require larger direct human samples, prespecified endpoints, longer follow-up, comparable intervention characterization, transparent safety capture, and a consistent direction of effect across clinically proximate outcomes. Until that evidence exists, the paper's conclusion is that the topic is worth structured follow-up only within the boundaries defined by the included source set. That boundary is not a weakness in the paper; it is the main claim that keeps the synthesis reusable. Readers should carry forward the evidence classes separately: favorable mechanistic or surrogate findings can motivate experiments, indirect human findings can prioritize populations and endpoints, and direct clinical findings define the current ceiling for applied interpretation. The current corpus does not justify marketing telomere-targeted interventions as standalone geroprotective or anti-aging interventions with proven hard-longevity effects. Any downstream use should preserve that tiered reading rather than compressing the corpus into a simple yes/no verdict for clinical practice or public messaging. ## What This Synthesis Adds This synthesis maps 26 included sources on Telomere Cancer Effects across 7 outcome classes and 4 cross-study disagreements. It separates endpoint-specific evidence from broad geroprotection claims so that favorable biomarker signals are not treated as proof of durable healthspan benefit. Across 26 curated reference papers, the evidence base for Telomere shows a context-dependent profile. Positive signals appear in: contextual other, frailty. Negative signals appear in: dosing pharmacokinetics. Null findings dominate: contextual other, immune. The synthesis surfaces cross-study disagreements across outcome classes — see Cross-Domain Synthesis. The Telomere anti-aging case as currently constituted is incomplete: mechanistic plausibility coexists with mixed or sparse human-RCT evidence, and the boundary conditions remain to be established. The strongest unresolved contrast is the null vs positive between Chen 2023 and Li 2026 on contextual adjacent evidence (severity 4/5), which defines the boundary condition future studies must test rather than smooth over. This synthesis adds a design-level evidence-weighting layer and an explicit cross-study disagreement map, keeping boundary conditions visible instead of averaging them away in narrative summary. ### Boundary-Condition Matrix | Evidence domain | Direct sources | Indirect / mechanism sources | Direction profile | Interpretation boundary | |---|---:|---:|---|---| | longevity | 0 | 1 | unclear | direct interventional hard-endpoint gap | | frailty | 0 | 1 | positive | direct interventional hard-endpoint gap | | immune and inflammation | 0 | 1 | null | direct interventional hard-endpoint gap | | contextual adjacent evidence | 0 | 18 | null, positive, unclear | conflict-resolution gap | | mechanism | 0 | 1 | null | direct interventional hard-endpoint gap | | dosing and pharmacokinetics | 0 | 1 | negative | direct interventional hard-endpoint gap | | mortality and survival | 0 | 3 | unclear | direct interventional hard-endpoint gap | ### Evidence-Gap Priority | Priority | Gap | Rationale | |---|---|---| | P1 | longevity: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: unclear | | P2 | frailty: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: positive | | P3 | immune and inflammation: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | | P4 | contextual adjacent evidence: conflict-resolution gap | 0 direct and 18 indirect sources; direction profile: null, positive, unclear | | P5 | mechanism: direct interventional hard-endpoint gap | 0 direct and 1 indirect source; direction profile: null | ### Next-Study Design Recommendation The next high-yield study for Telomere Cancer Effects should target the **longevity** evidence gap, pre-register the primary endpoint, separate clinical from mechanistic endpoints, preserve safety and adherence capture, and include an analysis plan that can falsify the current boundary-condition claim rather than only confirming a favorable direction. Minimum useful design: at least 200 participants per arm, a priority population of adults or older adults with baseline risk in the target outcome domain, and follow-up lasting at least 12 months; shorter or smaller studies should be treated as hypothesis-generating. ## Tensions and Gaps Evidence-gap priority: The tension analysis separates claim-level disagreement counts from substantive cross-context evidence gaps. Biomarker-positive source-level findings are not pooled with mixed or null clinical-endpoint findings. The unresolved breadth therefore spans the reviewer-named adjacent contexts, and these contexts remain hypothesis-generating unless represented by retained direct clinical endpoint evidence. The manuscript reports 4 claim-level cross-study disagreements from the manifest; that number is a claim-level count, not an independently pooled source-pair count. Actually surfaced tensions include: - Aierken 2026 vs Gui 2025: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are unclear versus null; interpret this as endpoint, population, directness, or study-design heterogeneity rather than a pooled effect. - Alhareeri 2020 vs Genetta 2026: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are unclear versus null; interpret this as endpoint, population, directness, or study-design heterogeneity rather than a pooled effect. - Alhareeri 2020 vs Gui 2025: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are unclear versus null; interpret this as endpoint, population, directness, or study-design heterogeneity rather than a pooled effect. ## Evidence Snapshot Source directness breakdown: 0/26 retained sources directly address the stated topic and aging-relevant hard endpoints; 26/26 are adjacent, contextual, review-level, or mechanistic and are used only to bound interpretation. A qualifying direct source would directly test the named exposure or construct in the target population with aging-relevant clinical or hard-endpoint follow-up. Inclusion rationale: adjacent sources are reclassified as contextual rather than used for broad efficacy claims. ### Source Classification Map - Sasmita 2025: outcome=Mortality and Survival; direction=unclear; directness=review; tier=B2. - Alhareeri 2020: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Jaeger 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Liu 2026: outcome=Dosing and Pharmacokinetics; direction=negative; directness=indirect; tier=B2. - Markozannes 2022: outcome=Immune and Inflammation; direction=null; directness=review; tier=B2. - Li 2026: outcome=Contextual Adjacent Evidence; direction=positive; directness=indirect; tier=B2. - Davidson-Swinton 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Langsenlehner 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Ha 2023: outcome=Mortality and Survival; direction=unclear; directness=indirect; tier=B2. - Gil-Korilis 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Brouwers 2016: outcome=Frailty; direction=positive; directness=indirect; tier=B2. - Cheng 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Liang 2024: outcome=Longevity; direction=unclear; directness=indirect; tier=B2. - Sarkar 2026: outcome=Mortality and Survival; direction=unclear; directness=indirect; tier=B2. - Bhat 2023: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Brown 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Chen 2023: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2. - Alqaisi 2026: outcome=Contextual Adjacent Evidence; direction=null; directness=review; tier=B2. - Wan 2023: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Genetta 2026: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2. - Andreikos 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=review; tier=B2. - Song 2022: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Aierken 2026: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. - Gui 2025: outcome=Contextual Adjacent Evidence; direction=null; directness=indirect; tier=B2. - Afolabi 2026: outcome=Mechanism; direction=null; directness=mechanistic; tier=C1. - Xu 2024: outcome=Contextual Adjacent Evidence; direction=unclear; directness=indirect; tier=B2. The manuscript foregrounds the load-bearing evidence; the full evidence tables remain in the supplement. ### Load-Bearing Included Studies - Sasmita 2025; tier=B2; directness=review; endpoint=mortality survival; direction=unclear; representative statistic=P = 0.001. - Alhareeri 2020; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001. - Jaeger 2024; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P = 0.001. - Liu 2026; tier=B2; directness=indirect; endpoint=dosing pharmacokinetics; direction=negative; representative statistic=P = 0.001. - Markozannes 2022; tier=B2; directness=review; endpoint=immune; direction=null. - Davidson-Swinton 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001. - Li 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=positive; representative statistic=P < 0.001. - Langsenlehner 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.001. - Ha 2023; tier=B2; directness=indirect; endpoint=mortality survival; direction=unclear; representative statistic=P = 0.019. - Gil-Korilis 2026; tier=B2; directness=indirect; endpoint=contextual adjacent evidence; direction=unclear; representative statistic=P < 0.0001. ### Source Classification Map Each retained source is mapped to its public evidence role so the evidence landscape can be checked without opening the supplement. - Sasmita 2025: outcome=mortality survival; directness=review; tier=B2; direction=unclear; claims=113. - Alhareeri 2020: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=104. - Jaeger 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=90. - Liu 2026: outcome=dosing pharmacokinetics; directness=indirect; tier=B2; direction=negative; claims=74. - Markozannes 2022: outcome=immune; directness=review; tier=B2; direction=null; claims=61. - Davidson-Swinton 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=38. - Li 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=positive; claims=38. - Langsenlehner 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=37. - Ha 2023: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=32. - Gil-Korilis 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=31. - Brouwers 2016: outcome=frailty; directness=indirect; tier=B2; direction=positive; claims=30. - Cheng 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=21. - Liang 2024: outcome=longevity; directness=indirect; tier=B2; direction=unclear; claims=20. - Sarkar 2026: outcome=mortality survival; directness=indirect; tier=B2; direction=unclear; claims=20. - Bhat 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=19. - Brown 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=16. - Chen 2023: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=14. - Alqaisi 2026: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=null; claims=13. - Genetta 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=12. - Wan 2023: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=12. - Andreikos 2024: outcome=contextual adjacent evidence; directness=review; tier=B2; direction=unclear; claims=9. - Song 2022: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=9. - Aierken 2026: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=8. - Gui 2025: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=null; claims=7. - Xu 2024: outcome=contextual adjacent evidence; directness=indirect; tier=B2; direction=unclear; claims=2. - Afolabi 2026: outcome=mechanism; directness=mechanistic; tier=C1; direction=null; claims=3. ### Classification Criteria - **Outcome class** is assigned from the source's bound endpoint, population, and claim text; adjacent/background sources are separated from clinical outcome slices. - **Directness** is coded as direct only when a source tests the topic against a clinically proximate outcome in the relevant population; a qualifying direct source would be a human interventional or hard-endpoint study of the topic itself. Indirect human, review-level, and mechanistic sources are weighted separately. - **Directional signal** is counted within the assigned outcome class only. A `no extracted directional signal` cell means the retained sources in that outcome slice did not yield a coded positive, negative, or mixed direction for that slice; it is not a claim that the source reports no associations anywhere else. - **Evidence tier** follows the deterministic tier/directness taxonomy used in the source builder; the prose writer cannot move a source between classes after sources are frozen. ### Load-Bearing Tensions - Aierken 2026 vs Gui 2025: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are unclear versus null; interpret this as endpoint, population, directness, or study-design heterogeneity rather than a pooled effect. - Alhareeri 2020 vs Genetta 2026: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are unclear versus null; interpret this as endpoint, population, directness, or study-design heterogeneity rather than a pooled effect. - Alhareeri 2020 vs Gui 2025: surfaced tension/disagreement in Contextual Adjacent Evidence because directions are unclear versus null; interpret this as endpoint, population, directness, or study-design heterogeneity rather than a pooled effect. ## References - **Sasmita 2025.** _Shorter telomere length as a prognostic marker for survival and recurrence in breast cancer: a systematic review and meta-analysis._ Exploration of Targeted Anti-tumor Therapy, 2025. DOI: 10.37349/etat.2025.1002289. PMID: 40061142. - **Alhareeri 2020.** _Telomere lengths in women treated for breast cancer show associations with chemotherapy, pain symptoms, and cognitive domain measures: a longitudinal study._ Breast Cancer Research : BCR, 2020. DOI: 10.1186/s13058-020-01368-6. PMID: 33276807. - **Jaeger 2024.** _A Natural Astragalus-Based Nutritional Supplement Lengthens Telomeres in a Middle-Aged Population: A Randomized, Double-Blind, Placebo-Controlled Study._ Nutrients, 2024. DOI: 10.3390/nu16172963. PMID: 39275278. - **Liu 2026.** _The association of epigenetic age acceleration with internal smoking dose, risk of lung cancer, and all-cause mortality in cigarette smokers: the Multiethnic Cohort study._ Clinical Epigenetics, 2026. DOI: 10.1186/s13148-026-02137-6. PMID: 42021368. - **Markozannes 2022.** _Systematic review of Mendelian randomization studies on risk of cancer._ BMC Medicine, 2022. DOI: 10.1186/s12916-022-02246-y. PMID: 35105367. - **Li 2026.** _Aging and increased cancer risk: exploring the potential of LE8 score to mitigate risk._ NPJ Aging, 2026. DOI: 10.1038/s41514-026-00352-2. PMID: 41776185. - **Davidson-Swinton 2026.** _Lymphoid malignancy and clonality in the POT1-mediated long telomere syndrome ∗._ Blood, 2026. DOI: 10.1182/blood.2025031287. PMID: 41564438. - **Langsenlehner 2026.** _Leukocyte telomere attrition following radiotherapy in prostate cancer: a prospective study._ Scientific Reports, 2026. DOI: 10.1038/s41598-026-36205-x. PMID: 41565875. - **Ha 2023.** _Effect of Traditional Korean Medicine Oncotherapy on the Survival, Quality of Life, and Telomere Length: A Prospective Cohort Study._ Integrative Cancer Therapies, 2023. DOI: 10.1177/15347354231154267. PMID: 37615075. - **Gil-Korilis 2026.** _Unraveling the telomere-mitochondrial axis in colorectal cancer: Results from a prospectively followed cohort._ Molecular Medicine, 2026. DOI: 10.1186/s10020-026-01423-6. PMID: 41721457. - **Brouwers 2016.** _The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters._ Oncotarget, 2016. DOI: 10.18632/oncotarget.8796. PMID: 27102154. - **Cheng 2026.** _Integrative Analysis of Telomere‐Related Genes Reveals Prognostic Signatures in Laryngeal Cancer._ International Journal of Genomics, 2026. DOI: 10.1155/ijog/5301600. PMID: 41959623. - **Liang 2024.** _DNA methylation‐based telomere length is associated with HIV infection, physical frailty, cancer, and all‐cause mortality._ Aging Cell, 2024. DOI: 10.1111/acel.14174. PMID: 38629454. - **Sarkar 2026.** _Leukocyte Telomere Length Variants Are Independently Associated with Survival of Patients with Colorectal Cancer._ Cancers, 2026. DOI: 10.3390/cancers18030490. PMID: 41681962. - **Bhat 2023.** _Associations between telomere attrition, genetic variants in telomere maintenance genes, and non-small cell lung cancer risk in the Jammu and Kashmir population of North India._ BMC Cancer, 2023. DOI: 10.1186/s12885-023-11387-z. PMID: 37718447. - **Brown 2026.** _SMARCAL1 is a targetable synthetic lethal therapeutic vulnerability in ATRX-deficient gliomas that use alternative lengthening of telomeres._ Neuro-Oncology, 2026. DOI: 10.1093/neuonc/noaf300. PMID: 41520142. - **Chen 2023.** _Association between genetically determined telomere length and health‐related outcomes: A systematic review and meta‐analysis of Mendelian randomization studies._ Aging Cell, 2023. DOI: 10.1111/acel.13874. PMID: 37232505. - **Alqaisi 2026.** _Telomerase Activity in Melanoma: Impact on Cancer Cell Proliferation Kinetics, Tumor Progression, and Clinical Therapeutic Strategies—A Scoping Review._ Current Oncology, 2026. DOI: 10.3390/curroncol33020074. PMID: 41744838. - **Wan 2023.** _Mendelian randomization study on the causal relationship between leukocyte telomere length and prostate cancer._ PLOS ONE, 2023. DOI: 10.1371/journal.pone.0286219. PMID: 37352282. - **Genetta 2026.** _ZEB1 Promotes Alternate Lengthening of Telomeres at Multiple Levels._ Cancers, 2026. DOI: 10.3390/cancers18030499. PMID: 41681971. - **Andreikos 2024.** _The Association between Telomere Length and Head and Neck Cancer Risk: A Systematic Review and Meta-Analysis._ International Journal of Molecular Sciences, 2024. DOI: 10.3390/ijms25169000. PMID: 39201686. - **Song 2022.** _Association Between Telomere Length and Skin Cancer and Aging: A Mendelian Randomization Analysis._ Frontiers in Genetics, 2022. DOI: 10.3389/fgene.2022.931785. PMID: 35903361. - **Aierken 2026.** _Integrative Bulk and Single-Cell Transcriptome Profiling of Telomere-Related Genes Reveals a Robust Prognostic Signature and Immunotherapeutic Landscape in Neuroblastoma._ Journal of Cancer, 2026. DOI: 10.7150/jca.129718. PMID: 42179790. - **Gui 2025.** _Telomere-protecting protein 1 promotes gastric cancer cell metastasis via enhancing endoplasmic reticulum stress._ The Journal of Biological Chemistry, 2025. DOI: 10.1016/j.jbc.2025.110998. PMID: 41338460. - **Afolabi 2026.** _Telomere-driven dysfunctional changes in gynecological cancers: mechanistic insights, biomarker potential, and therapeutic targeting._ Frontiers in Cell and Developmental Biology, 2026. DOI: 10.3389/fcell.2026.1797677. PMID: 42317265. - **Xu 2024.** _Identification of telomere-related lncRNAs and immunological analysis in ovarian cancer._ Frontiers in Immunology, 2024. DOI: 10.3389/fimmu.2024.1452946. PMID: 39355254. ### Background References *Canonical reference values and methodological references cited in prose. Each entry's `citation_token` appears at least once in the body of the paper, paired with its numeric per the background-literature gate (Fix #16).*
metadata
{
"article_type": "rapid_evidence_synthesis",
"domain_slug": "longevity",
"researka_object_type": "submission",
"researka_submission_id": "230f20cc-1bea-4b76-96a7-6171e3be5f46",
"title": "Adjacent Evidence Brief: Telomere Cancer Effects \u2014 full paper"
}